par Bunel, Valérian 
;Berghmans, Thierry
Référence Revue des Maladies Respiratoires Actualites, 6, 2, page (121-125)
Publication Publié, 2014
;Berghmans, Thierry Référence Revue des Maladies Respiratoires Actualites, 6, 2, page (121-125)
Publication Publié, 2014
Article révisé par les pairs
| Résumé : | Over 85 % of patients with non small cell lung carcinoma (NSCLC) have no EGFR activating mutation, their management in first line treatment is the daily life of doctors who have interest in lung cancer. Chemotherapy proved to be useful compared to supportive care from many years. The standard chemotherapy regimen should be a platinumbased combination, first with cisplatin if the patient's condition and comorbidities allow it. Combination therapy rather than monotherapy is beneficial, including elderly patients or those with a performance status 2. If cisplatin can't be used, a combination therapy with or without carboplatin can be chosen. The choice of the second agent. in combination with cisplatin should be guided by the potential side effects and the histology, strategies based on the presence of an overactivation of some proteins (for example ERCC1) have not yet proven their effectiveness. Except adding bevacizumab to combination therapy, there is no place for targeted therapies in first-line treatment of NSCLC. © 2014 Elsevier Masson SAS. |
